NCT00028002 2020-10-26
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
7 trialsNCT00324987 2017-09-14
S0502
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00030667 2015-04-15
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
National Cancer Institute (NCI)
Phase 2 Completed
NCT00009906 2014-12-23
Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00041197 2013-07-16
Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00091078 2013-06-05
Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00025246 2013-02-20
Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
National Cancer Institute (NCI)
Phase 2 Completed